Limits...
Expression of Th-17 and RORγt mRNA in Behçet's Disease.

Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A - Med. Sci. Monit. (2011)

Bottom Line: The percentage of circulating Th17 cells and the ability to produce interleukin-17A (IL-17A) were increased in samples derived from patients with active BD, MS and SLE patients.RORγt determined Th17 cell might be involved with increased IL-17A in BD.Our results indicate that IL-17 contributes to the active proinflammatory pattern that is characteristic of inflammatory diseases and patients with active BD.

View Article: PubMed Central - PubMed

Affiliation: Tunis El Manar University, Medicine Faculty of Tunis, Tunisia. kamel.hamzaoui@gmail.com

ABSTRACT

Background: To investigate plasma IL-17 level and the expression of Th17 cell transcription factor RORγt in the pathogenesis of Behçet's Disease (BD).

Material/methods: Blood samples were collected from 73 patients with BD (45 patients were in active stage), 20 systemic lupus erythematosus (SLE) and 12 multiple sclerosis patients (MS). Twelve patients with BD were investigated both in their active and remission stages. Samples were processed to detect IL-17A level in plasma by enzyme-linked immunosorbent assay (ELISA). Related gene expression was assessed by real-time reverse transcription polymerase chain reaction. Function of Th17 cells in active BD patients with erythema nodosum (EN)-like eruption was studied in relation to human umbilical vein endothelial cells (HUVECs).

Results: We demonstrated the presence of Th17 cells and RORγt among the peripheral blood mononuclear cells (PBMC). The percentage of circulating Th17 cells and the ability to produce interleukin-17A (IL-17A) were increased in samples derived from patients with active BD, MS and SLE patients. We observed that IL-17A from patients with active BD could induce adhesion molecule messenger RNA expression in HUVECs.

Conclusions: RORγt determined Th17 cell might be involved with increased IL-17A in BD. Our results indicate that IL-17 contributes to the active proinflammatory pattern that is characteristic of inflammatory diseases and patients with active BD.

Show MeSH

Related in: MedlinePlus

Plasma IL-17A level in Behçet’s Disease (BS), systemic lupus erythematosus (SLE) patients, multiple sclerosis patients (MS) and healthy controls (HC). (A): Box indicating IL-17A level in active BD patients (n=45), remission BD stage (n=28), SLE patients (n=20), MS patients (n=12) and in HC (n=40). The control diseases (SLE and MS patients) were in active disease (B): Box plot indicating elevated levels of IL-17A in 12 BD patients studied respectively in active and in remission stages after 8 to 10 months of treatment. The medians are indicated by a line inside each box, the 25th and 75th percentiles by the box limits, the lower and upper error bars represent the 10th and 90th percentiles, respectively. (*): Comparison between active BD patients and SLE patients, (P=0.0015).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539514&req=5

f1-medscimonit-17-4-cr227: Plasma IL-17A level in Behçet’s Disease (BS), systemic lupus erythematosus (SLE) patients, multiple sclerosis patients (MS) and healthy controls (HC). (A): Box indicating IL-17A level in active BD patients (n=45), remission BD stage (n=28), SLE patients (n=20), MS patients (n=12) and in HC (n=40). The control diseases (SLE and MS patients) were in active disease (B): Box plot indicating elevated levels of IL-17A in 12 BD patients studied respectively in active and in remission stages after 8 to 10 months of treatment. The medians are indicated by a line inside each box, the 25th and 75th percentiles by the box limits, the lower and upper error bars represent the 10th and 90th percentiles, respectively. (*): Comparison between active BD patients and SLE patients, (P=0.0015).

Mentions: Plasma IL-17A level in BD patients, SLE patients, MS patients and normal controls were shown in (Figure 1A). Patients with active BD expressed similar level of IL-17A (20.94±3.96 pg/ml) compared to MS patients (22.45±4.21 pg/ml; P=0.25). However active BD patients expressed low IL-17A level when compared to SLE patients (24.26±3.02 pg/ml; P=0.0015). No significant difference was observed between MS and SLE patients (P=0.170). Significant differences were observed between active BD and remission BD (11.22±3.49 pg/ml; P=0.0001). No differences in IL-17 levels were found between healthy controls (11.045±4.33; pg/ml) and remission BD patients (P=0.858).


Expression of Th-17 and RORγt mRNA in Behçet's Disease.

Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A - Med. Sci. Monit. (2011)

Plasma IL-17A level in Behçet’s Disease (BS), systemic lupus erythematosus (SLE) patients, multiple sclerosis patients (MS) and healthy controls (HC). (A): Box indicating IL-17A level in active BD patients (n=45), remission BD stage (n=28), SLE patients (n=20), MS patients (n=12) and in HC (n=40). The control diseases (SLE and MS patients) were in active disease (B): Box plot indicating elevated levels of IL-17A in 12 BD patients studied respectively in active and in remission stages after 8 to 10 months of treatment. The medians are indicated by a line inside each box, the 25th and 75th percentiles by the box limits, the lower and upper error bars represent the 10th and 90th percentiles, respectively. (*): Comparison between active BD patients and SLE patients, (P=0.0015).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539514&req=5

f1-medscimonit-17-4-cr227: Plasma IL-17A level in Behçet’s Disease (BS), systemic lupus erythematosus (SLE) patients, multiple sclerosis patients (MS) and healthy controls (HC). (A): Box indicating IL-17A level in active BD patients (n=45), remission BD stage (n=28), SLE patients (n=20), MS patients (n=12) and in HC (n=40). The control diseases (SLE and MS patients) were in active disease (B): Box plot indicating elevated levels of IL-17A in 12 BD patients studied respectively in active and in remission stages after 8 to 10 months of treatment. The medians are indicated by a line inside each box, the 25th and 75th percentiles by the box limits, the lower and upper error bars represent the 10th and 90th percentiles, respectively. (*): Comparison between active BD patients and SLE patients, (P=0.0015).
Mentions: Plasma IL-17A level in BD patients, SLE patients, MS patients and normal controls were shown in (Figure 1A). Patients with active BD expressed similar level of IL-17A (20.94±3.96 pg/ml) compared to MS patients (22.45±4.21 pg/ml; P=0.25). However active BD patients expressed low IL-17A level when compared to SLE patients (24.26±3.02 pg/ml; P=0.0015). No significant difference was observed between MS and SLE patients (P=0.170). Significant differences were observed between active BD and remission BD (11.22±3.49 pg/ml; P=0.0001). No differences in IL-17 levels were found between healthy controls (11.045±4.33; pg/ml) and remission BD patients (P=0.858).

Bottom Line: The percentage of circulating Th17 cells and the ability to produce interleukin-17A (IL-17A) were increased in samples derived from patients with active BD, MS and SLE patients.RORγt determined Th17 cell might be involved with increased IL-17A in BD.Our results indicate that IL-17 contributes to the active proinflammatory pattern that is characteristic of inflammatory diseases and patients with active BD.

View Article: PubMed Central - PubMed

Affiliation: Tunis El Manar University, Medicine Faculty of Tunis, Tunisia. kamel.hamzaoui@gmail.com

ABSTRACT

Background: To investigate plasma IL-17 level and the expression of Th17 cell transcription factor RORγt in the pathogenesis of Behçet's Disease (BD).

Material/methods: Blood samples were collected from 73 patients with BD (45 patients were in active stage), 20 systemic lupus erythematosus (SLE) and 12 multiple sclerosis patients (MS). Twelve patients with BD were investigated both in their active and remission stages. Samples were processed to detect IL-17A level in plasma by enzyme-linked immunosorbent assay (ELISA). Related gene expression was assessed by real-time reverse transcription polymerase chain reaction. Function of Th17 cells in active BD patients with erythema nodosum (EN)-like eruption was studied in relation to human umbilical vein endothelial cells (HUVECs).

Results: We demonstrated the presence of Th17 cells and RORγt among the peripheral blood mononuclear cells (PBMC). The percentage of circulating Th17 cells and the ability to produce interleukin-17A (IL-17A) were increased in samples derived from patients with active BD, MS and SLE patients. We observed that IL-17A from patients with active BD could induce adhesion molecule messenger RNA expression in HUVECs.

Conclusions: RORγt determined Th17 cell might be involved with increased IL-17A in BD. Our results indicate that IL-17 contributes to the active proinflammatory pattern that is characteristic of inflammatory diseases and patients with active BD.

Show MeSH
Related in: MedlinePlus